Real-world outcomes in a Latin American setting with first-line osimertinib in EGFR-mutated NSCLC.

Authors: Daniela Patino-Hernandez, Ricardo Elias Bruges, July Andrea Russi Noguera, Nicolás Martínez, Ricardo Ballesteros

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20682

Source: Full article

---

Abstract

e20682